July 2020
https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7379157/"The Evolving Role of Diet in Prostate Cancer Risk and ProgressionRecent data have further solidified the association between insulin resistance and prostate cancer.............
Regarding therapeutics, hyperinsulinemia may be the cause of resistance to PI3K inhibitors in the treatment of prostate cancer, leading to new investigations combining these drugs with ketogenic diets.
Summary:
Given the recently available data regarding insulin resistance and adipokine influence on prostate cancer, dietary strategies targeting metabolic syndrome, diabetes and obesity should be further explored..............
Elevated BMI is also a risk factor for the progression of low grade to high grade prostate cancer [7]. The homeostatic model assessment of insulin resistance, or HOMA-IR, has now been shown to be associated with prostate cancer risk in a recent meta-analysis, with previous studies showing obesity correlating with higher grade and Gleason score at diagnosis, as well as higher recurrence rates and poorer prognosis.........................
Metabolic Disease and Prostate Cancer
Several studies have examined the impact of various components of metabolic syndrome and their effect on prostate cancer. Data from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) revealed a strong association between metabolic syndrome and the incidence of high grade prostate cancer [12]. In this study, 8122 men were randomized to placebo or dutasteride following a negative prostate biopsy. Patients then underwent biopsies at 2 and 4 years, with BMI, hypertension, hypercholesterolemia, and diabetes risk factors recorded. Study results revealed that the presence of 3 or more metabolic syndrome components was significantly associated with increased risk of high grade prostate cancer (OR 1.94, p=0.017).........................
Obesity has also been linked with prostate cancer progression. In a study of 565 men from Canada, men undergoing active surveillance were found to have a 50% increase in prostate cancer progression for every 5 point increase in BMI over 25 [7]. A meta-analysis demonstrated that obesity was particularly associated with an increased risk of aggressive prostate cancer.................
Ketosis may offer unique benefits in cancer prevention and prognosis above and beyond carbohydrate restriction.
Ketosis induces many physiologic changes that can be leveraged for therapeutic benefit. The historic work at Johns Hopkins University pioneered the use of the
ketogenic diet in the treatment of refractory pediatric epilepsy in the 1920’s, with staggering results [61]. The early work was validated in extensive clinical studies over the years, with systematic reviews and meta-analysis demonstrating the efficacy of the ketogenic diet for this condition[62]. Currently, a number of ketogenic diet-based clinical trials are ongoing in several disease states, including adult epilepsy, metabolic syndrome, diabetes mellitus type II, Alzheimer’s disease, and cancer.
Of particular relevance to cancer and the mechanisms described previously, the ketogenic diet reduces insulin resulting in downregulation of oncogenic signaling pathways, decreases circulating glucose leading to decreased tumor biomass production, and increases ketone bodies with direct HDAC inhibition [38,47,63]. In light of these promising mechanisms, it is not surprising that the ketogenic diet has been shown to be efficacious as an adjuvant to numerous cancers in clinical studies, including ovarian, endometrial, pancreatic, and lung cancers [64,65]. While there are currently limited clinical studies evaluating outcomes of the ketogenic diet among prostate cancer patients, a recent review suggested that the anti-cachectic properties of ketones could be beneficial as adjuvant treatment [66]. The ketogenic diet is currently being evaluated for prostate cancer patients under active surveillance (NCT02194516)................................................".
Post Edited (BillyBob@388) : 10/15/2020 2:38:42 PM (GMT-6)